Fig. 5.

High levels of BCL9 and BCL9L correlate with poor survival only in HCCs with inactive Wnt signaling. BCL9 and BCL9L expression values and survival data of the TCGA-LIHC cohort were retrieved from http://www.oncolnc.org/ [16] and stratified into Wnt-inactive and Wnt-active HCCs according to Sanchez-Vega et al. [17]. BCL9 and BCL9L expression was classified as high (upper median) or low (lower median) and, for combined survival analysis, patients were grouped into the following BCL9–BCL9L expression groups: high–high, high–low, low–high, and low–low. The tables show the corresponding p values for the combined BCL9–BCL9L survival analysis as determined by log-rank test with Benjamini–Hochberg correction for multiple testing. Survival was analyzed according to Kaplan–Meier